10-Q: NovaBay Pharmaceuticals Reports First Quarter 2024 Results, Completes DERMAdoctor Divestiture

NovaBay Pharmaceuticals reported its first quarter 2024 results, including a net loss of $3.2 million, and completed the sale of its DERMAdoctor subsidiary.

Summary

• NovaBay Pharmaceuticals reported a net loss of $3.2 million for the first quarter of 2024, compared to a net loss of $1.7 million for the same period in 2023.
• The company's product revenue increased by 13% to $2.6 million, driven by growth in Avenova branded products.
• Operating expenses increased to $4.2 million, primarily due to higher general and administrative costs.
• A significant loss of $0.9 million was recorded from the divestiture of the DERMAdoctor subsidiary.
• The company's cash and cash equivalents decreased to $1.8 million as of March 31, 2024, from $2.9 million at the end of 2023.
• NovaBay continues to face challenges related to its ability to continue as a going concern, with ongoing operating losses and negative cash flows.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive revenue growth but significant losses, a concerning cash position, and a going concern warning. The divestiture of DERMAdoctor is a positive strategic move, but the overall financial health of the company is weak.

Positives

• Product revenue saw a 13% increase, indicating growth in core product sales.
• The divestiture of DERMAdoctor streamlines the business and reduces cash burn.
• The company recognized non-cash gains from changes in the fair value of warrant liabilities and embedded derivative liability.

Negatives

• The company reported a net loss of $3.2 million, a significant increase compared to the same period last year.
• Operating expenses increased by 44%, driven by higher general and administrative costs.
• The DERMAdoctor divestiture resulted in a loss of $0.9 million.
• Cash and cash equivalents decreased to $1.8 million, raising concerns about liquidity.
• The company's ability to continue as a going concern is in doubt due to ongoing losses and negative cash flows.

Risks

• The company's ability to continue as a going concern is in doubt due to ongoing losses and negative cash flows.
• The company may need to raise additional capital through debt or equity financing.
• The company is subject to the risk of delisting from the NYSE American if it does not meet continued listing requirements.
• The company relies on a single contract manufacturer, which could lead to supply chain issues.
• The company faces risks related to customer concentration, with a significant portion of revenue coming from a few major partners.

Future Outlook

The company expects to continue incurring operating losses and negative cash flows until revenues reach a level sufficient to support ongoing growth and operations. The company is evaluating different plans and strategic transactions to fund operations, including raising additional capital, reducing spending, out-licensing products, and divesting certain business lines.

Management Comments

• The company continues to evaluate strategies for the entire Company, to maximize revenue growth and profitability and minimize operating losses while addressing our capital and liquidity needs.
• The DERMAdoctor Divestiture streamlined our business by reducing our cash burn and allows us to focus on pursuing better growth opportunities.

Industry Context

The company operates in the eyecare and wound care markets, which are competitive and subject to changing market conditions. The company's performance is influenced by factors such as consumer demand, competition, and regulatory approvals. The divestiture of DERMAdoctor reflects a strategic shift to focus on core business areas.

Comparison to Industry Standards

• The company's revenue growth of 13% is a positive sign, but the significant net loss and cash burn are concerning compared to industry benchmarks.
• The company's reliance on a single contract manufacturer is a risk, as many companies in the pharmaceutical industry diversify their supply chains.
• The company's customer concentration risk is higher than some of its peers, as a significant portion of revenue comes from a few major partners.
• The company's operating loss of $2.4 million is a significant concern compared to other companies in the sector, many of which are profitable or have a clear path to profitability.
• The company's cash position of $1.8 million is low compared to industry standards, raising concerns about its ability to fund operations and growth.

Stakeholder Impact

• Shareholders face the risk of further share price decline and potential delisting from the NYSE American.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may experience changes in product availability or service due to the company's financial challenges.
• Suppliers may face increased scrutiny or changes in payment terms due to the company's liquidity concerns.
• Creditors face the risk of non-payment or restructuring of debt obligations.

Next Steps

• The company must submit a plan of compliance to the NYSE American by May 18, 2024.
• The company must regain compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide by October 18, 2025.
• The company will continue to evaluate different plans and strategies to address its capital and liquidity needs.
• The company will seek stockholder approval for the conversion of the Unsecured Convertible Notes and the exercise of the March 2024 Warrant.

Key Dates

Keywords

NovaBay Pharmaceuticals, Avenova, DERMAdoctor, Divestiture, Financial Results, Net Loss, Revenue, Warrants, Convertible Notes, Liquidity, Going Concern